Work

Blood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx380.084

Authors: T.S.K. Mok, S. Gadgeel, E.S. Kim, V. Velcheti, S. Hu, T. Riehl, E. Schleifman, S.M. Paul, S. Mocci, D.S. Shames, S. Phan, C. Yun, M. Mathisen, M. Kowanetz, U. Sweere, M.A. Socinski

Institutions: Chinese University of Hong Kong, University of Michigan, Carolinas Healthcare System, Levine Cancer Institute, Cleveland Clinic, Genentech, F. Hoffmann-La Roche AG, Florida Hospital Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2762263371

FWCI: 0.964

Cites:

Cited by: 15

Related to: 10